Helmedix Pty Ltd.
Treating autoimmune disorders with peptides from parasitic worms
This article was originally published in Start Up
Medical researchers now perceive an upside to parasitic worms; several groups around the world are looking to leverage helminths’ ability to suppress a host’s immune system enough to ensure their survival, which may help calm non-viral autoimmune diseases. The founders and backers of Helmedix Pty Ltd. of Sydney, Australia, aim to develop synthetic versions of parasite-secreted molecules shown to diminish a host’s normal immune response, and turn them into peptide drugs.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.